A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer

NCT04557384 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
3
Enrollment
INDUSTRY
Sponsor class

Stopped Study terminated due to inadequate PK profile associated with the subcutaneous formulation.

Conditions

Interventions

Sponsor

Eli Lilly and Company